The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis

Shock

Volumn 36, Issue 5, 2011, Pages 517-523

  Barratt Due, Andreas ^a   Johansen, Harald Thidemann ^b   Sokolov, Andrey ^a   Thorgersen, Ebbe Billmann ^a   Hellerud, Bernt Christian ^a   Reubsaet, Jan Leo ^b   Seip, Knut Fredrik ^b   Tønnessen, Tor Inge ^a   Lindstad, Julie Katrine ^a   Pharo, Anne ^a   Castellheim, Albert ^a,c   Mollnes, Tom Eirik ^a   Nielsen, Erik Waage ^d,e,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b School of Pharmacy   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d NORDLAND HOSPITAL   (Norway)

^e NORD UNIVERSITY   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

Author keywords

BK1 5; edema; Sepsis

Indexed keywords

BRADYKININ; BRADYKININ DERIVATIVE; BRADYKININ[1-5]; CD11 ANTIGEN; CD11R3 ANTIGEN; ICATIBANT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CAPILLARY LEAK SYNDROME; CECUM; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; ESCHERICHIA COLI; HEMODYNAMICS; INFLAMMATION; INTESTINE INJURY; LEUKOPENIA; LIGATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NEUTROPHIL; NONHUMAN; PROTEIN BLOOD LEVEL; SHOCK; SWINE;

ANIMALS; BRADYKININ; EDEMA; INFLAMMATION; NEISSERIA MENINGITIDIS; RECEPTORS, BRADYKININ; SEPSIS; SHOCK; SWINE;

EID: 80054895055     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3182336a34     Document Type: Article

References (35)

1. Mason JW, Kleeberg U, Dolan P, Colman RW: Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann Intern Med 73:545-551, 1970.
2. McCarthty DA, Potter DE, Nicolaides ED: An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther 148:117-122, 1965.
3. Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ: Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294:263-269, 2000. (Pubitemid 30434696)
4. Kalter ES, Daha MR, ten Cate JW, Verhoef J, Bouma BN: Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 151: 1019-1027, 1985. (Pubitemid 15065973)
5. Pixley RA, Zellis S, Bankes P, DeLa Cadena RA, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW: Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 23:41-51, 1995.
6. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80, 1992.
7. Pixley RA, La Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB Jr: Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 140:897-906, 1992.
8. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M: C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 15:69-78, 2009.
9. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119:1497-1503, 2007. (Pubitemid 46855846)
10. Cruden NL, Newby DE: Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin Pharmacother 9:2383-2390, 2008.
11. Nielsen EW, Hellerud BC, Thorgersen EB, Castellheim A, Pharo A, Lindstad J, Tonnessen TI, Brandtzaeg P, Mollnes TE: A new dynamic porcine model of meningococcal shock. Shock 32:302-309, 2009.
12. Mogensen TH, Paludan SR, Kilian M, Ostergaard L: Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in speciesspecific patterns. J Leukoc Biol 80:267-277, 2006. (Pubitemid 44835500)
13. Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD: Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem 292:87-93, 2001. (Pubitemid 32417725)
14. Pruneau D, Luccarini JM, Defrene E, Paquet JL, Belichard P: Characterisation of bradykinin receptors from juvenile pig coronary artery. Eur J Pharmacol 297:53-60, 1996. (Pubitemid 26064509)
15. Rizzi A, Calo G, Amadesi S, Regoli D: Kinin B1 and B2 receptors in pig vessels: characterization of two monoreceptor systems. Naunyn Schmiedebergs Arch Pharmacol 356:662-670, 1997. (Pubitemid 27478970)
16. Van BW: Evaluation of hemoconcentration from hematocrit measurements. J Appl Physiol 32:712-713, 1972.
17. Saetre T, Lindgaard AK, Lyberg T: Systemic activation of coagulation and fibrynolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul Fibrinolysis 11:433-438, 2000. (Pubitemid 30618523)
18. Thorgersen EB, Hellerud BC, Nielsen EW, Barratt-Due A, Fure H, Lindstad JK, Pharo A, Fosse E, Tonnessen TI, Johansen HT, et al.: CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J 24:712-722, 2010.
19. Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M: Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med 34:3005-3010, 2006. (Pubitemid 44808745)
20. Marshall JC, Charbonney E, Gonzalez PD: The immune system in critical illness. Clin Chest Med 29:605-616, vii, 2008.
21. Frick IM, Bjorck L, Herwald H: The dual role of the contact system in bacterial infectious disease. Thromb Haemost 98:497-502, 2007. (Pubitemid 47412875)
22. Yekebas E, Treede H, Jochum M, Gippner-Steppert C, Bloechle C, Knoefel WT, Scholz J, Fink E, Izbicki JR: Bradykinin B2-receptor antagonism attenuates fatal cardiocirculatory breakdown induced by severe experimental pancreatitis. Crit Care Med 28:1119-1127, 2000. (Pubitemid 30262089)
23. Jonkam CC, Enkhbaatar P, Nakano Y, Boehm T, Wang J, Nussberger J, Esechie A, Traber LD, Herndon D, Traber DL: Effects of the bradykinin B2 receptor antagonist icatibant on microvascular permeability after thermal injury in sheep. Shock 28:704-709, 2007. (Pubitemid 350135476)
24. Renner J, Scholz J, Bein B: Monitoring fluid therapy. Best Pract Res Clin Anaesthesiol 23:159-171, 2009.
25. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A: The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99:6-38, 2005. (Pubitemid 41366887)
26. Marceau F, Regoli D: Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3:845-852, 2004. (Pubitemid 39405945)
27. Yayama K, Hiyoshi H, Sugiyama K, Okamoto H: The lipopolysaccharideinduced up-regulation of bradykinin B2-receptor in the mouse heart is mediated by tumor necrosis factor-alpha and angiotensin II. Biol Pharm Bull 29: 1143-1147, 2006. (Pubitemid 43845473)
28. Regoli DC, Marceau F, Lavigne J: Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 71:105-115, 1981. (Pubitemid 11112570)
29. Drapeau G, deBlois D, Marceau F: Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther 259:997-1003, 1991.
30. Schremmer-Danninger E, Offner A, Siebeck M, Heinz-Erian P, Gais P, Roscher AA: Autoradiographic visualization of B1 bradykinin receptors in porcine vascular tissues in the presence or absence of inflammation. Immunopharmacology 33:95-100, 1996. (Pubitemid 26247906)
31. Campanholle G, Landgraf RG, Borducchi E, Semedo P, Wang PH, Amano MT, Russo M, Pacheco-Silva A, Jancar S, Camara NO: Bradykinin inducible receptor is essential to lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 634:132-137, 2010.
32. Marmarou A, Guy M, Murphey L, Roy F, Layani L, Combal JP, Marquer C: A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J Neurotrauma 22:1444-1455, 2005. (Pubitemid 43122359)
33. Mann R, Woodson LC, Traber LD, Herndon DN, Traber DL: Role of bradykinin in ovine endotoxemia. Circ Shock 34:224-230, 1991.
34. Siebeck M, Spannagl E, Schorr M, Stumpf B, Fritz H, Whalley ET, Cheronis JC: Effect of combined B1 and B2 kinin receptor blockade in porcine endotoxin shock. Immunopharmacology 33:81-84, 1996. (Pubitemid 26247902)
35. Bovenzi V, Savard M, Morin J, Cuerrier CM, Grandbois M, Gobeil F Jr: Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J Cell Physiol 222:168-176, 2010.